Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13075-015-0765-4 http://scihub22266oqcxt.onion/10.1186/s13075-015-0765-4 C4559892!4559892 !26337145     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26337145 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Arthritis+Res+Ther 2015 ; 17 (1 ): 243 Nephropedia Template TP {{tp|p=26337145 |t=2015. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever |pdf=|usr=}}{{26337145 }} gab.com Text Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever JO: Arthritis Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=26337145 #FOAvip INTRODUCTION: This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients. METHOD: Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in period. Patients who had an attack during the first run-in period advanced to a second 30-day period. At the first attack, patients started to receive three canakinumab 150 mg subcutaneous injections at 4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the proportion of patients with 50 % or more reduction in attack frequency. Secondary outcome measures included time to next attack following last canakinumab dose and changes in quality of life assessed by SF-36. RESULTS: Thirteen patients were enrolled in the run-in period and 9 advanced to the treatment period. All 9 patients achieved a 50 % or more reduction in attack frequency, and only one patient had an attack during the treatment period. C-reactive protein and serum amyloid A protein levels remained low throughout the treatment period. Significant improvement was observed in both physical and mental component scores of the Short Form-36 at Day 8. Five patients had an attack during the 2-month follow-up, occurring median 71 (range, 31 to 78) days after the last dose. Adverse events were similar to those observed in the previous canakinumab trials. CONCLUSION: Canakinumab was effective at controlling the attack recurrence in patients with FMF resistant to colchicine. Further investigations are warranted to explore canakinumab's potential in the treatment of patients with colchicine resistant FMF. TRIAL REGISTRATION: ClinicalTrials.gov NCT01088880 . Registered 16 March 2010. Twit Text FOAVip Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever ????Arthritis Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=26337145 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26337145 #FOAvip English Wikipedia <ref>{{Cite pmid|26337145 }}</ref> Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever #MMPMID26337145 Gül A ; Ozdogan H ; Erer B ; Ugurlu S ; Kasapcopur O ; Davis N ; Sevgi S Arthritis Res Ther 2015[Sep]; 17 (1 ): 243 PMID26337145 show ga INTRODUCTION: This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients. METHOD: Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in period. Patients who had an attack during the first run-in period advanced to a second 30-day period. At the first attack, patients started to receive three canakinumab 150 mg subcutaneous injections at 4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the proportion of patients with 50 % or more reduction in attack frequency. Secondary outcome measures included time to next attack following last canakinumab dose and changes in quality of life assessed by SF-36. RESULTS: Thirteen patients were enrolled in the run-in period and 9 advanced to the treatment period. All 9 patients achieved a 50 % or more reduction in attack frequency, and only one patient had an attack during the treatment period. C-reactive protein and serum amyloid A protein levels remained low throughout the treatment period. Significant improvement was observed in both physical and mental component scores of the Short Form-36 at Day 8. Five patients had an attack during the 2-month follow-up, occurring median 71 (range, 31 to 78) days after the last dose. Adverse events were similar to those observed in the previous canakinumab trials. CONCLUSION: Canakinumab was effective at controlling the attack recurrence in patients with FMF resistant to colchicine. Further investigations are warranted to explore canakinumab's potential in the treatment of patients with colchicine resistant FMF. TRIAL REGISTRATION: ClinicalTrials.gov NCT01088880 . Registered 16 March 2010. |*Drug Resistance [MESH] |Adolescent [MESH] |Adult [MESH] |Antibodies, Monoclonal, Humanized [MESH] |Antibodies, Monoclonal/adverse effects/*therapeutic use [MESH] |C-Reactive Protein/metabolism [MESH] |Child [MESH] |Colchicine/pharmacology/*therapeutic use [MESH] |Drug Administration Schedule [MESH] |Familial Mediterranean Fever/*drug therapy [MESH] |Female [MESH] |Headache/chemically induced [MESH] |Humans [MESH] |Male [MESH] |Pilot Projects [MESH] |Surveys and Questionnaires [MESH] |Treatment Outcome [MESH] |Tubulin Modulators/pharmacology/therapeutic use [MESH] |Vomiting/chemically induced [MESH]Efficacy and safety of canakinumab in adolescents and adults with co(epmc).pdf DeepDyve Pubget Overpricing